MannKind Corporation (NASDAQ:MNKD) Reports Optimistic Data from a Stage 3 Clinical Research of AFREZZA in Patients Having Type 2 Diabetes


Dallas, Texas 08/15/2013 (Financialstrend) –  MannKind Corporation (NASDAQ:MNKD) has declared positive preliminary outcomes from Study 175, a stage 3 clinical study of AFREZZA® (insulin human [rDNA origin]) Inhalation Powder, an investigational, ultra fast-acting mealtime insulin treatment administered utilizing MannKind’s new-gen (Gen2) inhaler (also named the Dreamboat? inhaler), in sufferers having type 2 diabetes.

Mr. Alfred Mann, Chairman and CEO of MannKind Corporation, said, “We are delighted that Study 175 met its primary endpoint of presenting that AFREZZA, when appended to a regime of metformin with or without a 2nd or 3rd oral medicine, fabricated superior A1c reductions as against oral therapy alone.”

MannKind Corporation scrip touches peak

MannKind Corporation soared after the firm said that its gasped insulin Afrezza met the major objectives behind 2 late-phase researches, as the medicine developer prepares for one more push to get regulatory approval for its diabetes cure.

The scrip of the Valencia, Calif., company surged $1.20, or 14 per cent, to mark its closure at $7.85. Moreover, it also hit a 52-wek peak of $8.70 just after opening.

The company said that its preliminary outcomes from the study showed that Type 2 diabetes sufferers taking Afrezza in addition to the extensively utilized generic medicine metformin witnessed improved decreases in continuing blood sugar levels, called A1c levels as compared to those taking an oral medicine.

The study also showed that Afrezza helped in decreasing the blood sugar levels like another insulin cure in patients suffering from Type 1 diabetes.

The company announced that Afrezza is a sppedily acting insulin powder, which comes in single-use cartridges delivered with the help of an inhaler appointed Dreamboat.

In addition, the company also proposes to make use of outcomes from these researches in one additional application for approval it predicts to forward to the Food and Drug Administration (FDA) early in the fourth quarterly period.